Molecular profiling of male breast cancer by multigene panel testing: Implications for precision oncology

Molecular profiling of male breast cancer by multigene panel testing: Implications for precision oncology

IntroductionCompared with breast cancer (BC) in women, BC in men is a rare disease with genetic and molecular peculiarities. Therapeutic approaches for male BC (MBC) are currently extrapolated from the clinical management of female BC, although the disease does not exactly overlap in males and femal...

Full description

Bibliographic Details
Main Authors:	Virginia Valentini, Valentina Silvestri, Agostino Bucalo, Giulia Conti, Mina Karimi, Linda Di Francesco, Giulia Pomati, Silvia Mezi, Bruna Cerbelli, Maria Gemma Pignataro, Arianna Nicolussi, Anna Coppa, Giulia D’Amati, Giuseppe Giannini, Laura Ottini
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-01-01
Series:	Frontiers in Oncology
Subjects:	male breast cancer (MBC) tumor profiling targeted gene panel sequencing clinically actionable genetic variants tumor mutational burden (TMB) microsatellite instability (MSI)
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.1092201/full

Similar Items

A meta-analysis with systematic review: Efficacy and safety of immune checkpoint inhibitors in patients with advanced gastric cancer
by: Aya El Helali, et al.
Published: (2022-10-01)

An absolute approach to using whole exome DNA and RNA workflow for cancer biomarker testing
by: Richa Malhotra, et al.
Published: (2023-03-01)

Role of Immune Checkpoint Inhibitors in Gastrointestinal Malignancies
by: Anita Mazloom, et al.
Published: (2020-08-01)

Molecular Landscape of Small Bowel Adenocarcinoma
by: Karan Pandya, et al.
Published: (2022-03-01)

Molecular heterogeneity in histomorphologic subtypes of lung adeno carcinoma represents a challenge for treatment decision
by: Tobias Kolb, et al.
Published: (2024-03-01)

Pan-cancer analysis of the prognostic and immunological role of GJB2: a potential target for survival and immunotherapy
by: Yuting Jia, et al.
Published: (2023-06-01)

Investigation of an Alternative Marker for Hypermutability Evaluation in Different Tumors
by: Anqi Chen, et al.
Published: (2021-01-01)

Pan-cancer analyses reveal IGSF10 as an immunological and prognostic biomarker
by: Yongxia Zhou, et al.
Published: (2023-01-01)

Multigene Panel Sequencing Identifies a Novel Germline Mutation Profile in Male Breast Cancer Patients
by: Ayman Al Saati, et al.
Published: (2023-09-01)

Integrated analysis of NET‐DNA receptor CCDC25 in malignant tumors: Pan‐cancer analysis
by: Xianlin Cheng, et al.
Published: (2023-10-01)

Immunotherapy in small bowel adenocarcinoma: a potential role?
by: Francesco Vitiello, et al.
Published: (2024-01-01)

The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer
by: Giovanni Maria Iannantuono, et al.
Published: (2022-08-01)

Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer
by: Silvia Mezi, et al.
Published: (2021-03-01)

Improved NGS-based detection of microsatellite instability using tumor-only data
by: Ana Claudia Marques, et al.
Published: (2022-11-01)

Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer
by: Yuan‐sheng Zang, et al.
Published: (2019-08-01)

Prognostic and Predictive Cross-Roads of Microsatellite Instability and Immune Response to Colon Cancer
by: Luigi Laghi, et al.
Published: (2020-12-01)

STR Profiling Reveals Tumor Genome Instability in Primary Mediastinal B-Cell Lymphoma
by: Natalya Risinskaya, et al.
Published: (2022-05-01)

Challenges and Future Directions in the Management of Tumor Mutational Burden-High (TMB-H) Advanced Solid Malignancies
by: Jibran Ahmed, et al.
Published: (2023-12-01)

Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB
by: Meng-Ta Sung, et al.
Published: (2022-05-01)

The prognostic value of tumor mutation burden (TMB) and its relationship with immune infiltration in breast cancer patients
by: Shengjin Cui, et al.
Published: (2023-02-01)

Relationship between tumor mutational burden, gene mutation status, and clinical characteristics in 340 cases of lung adenocarcinoma
by: Kai Ma, et al.
Published: (2022-11-01)

Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution
by: Svetlana N. Aleksakhina, et al.
Published: (2024-04-01)

Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies
by: Paraskevi Vryza, et al.
Published: (2023-12-01)

<i>WRN</i>-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype
by: Kai Zimmer, et al.
Published: (2020-05-01)

Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer
by: Yanan Cheng, et al.
Published: (2023-09-01)

TMB in NSCLC: A Broken Dream?
by: Sara Bravaccini, et al.
Published: (2021-06-01)

Long-term benefit of immunotherapy in a patient with squamous lung cancer exhibiting mismatch repair deficient/high microsatellite instability/high tumor mutational burden: A case report and literature review
by: Na Li, et al.
Published: (2023-01-01)

Gender-Specific Genetic Predisposition to Breast Cancer: <i>BRCA</i> Genes and Beyond
by: Virginia Valentini, et al.
Published: (2024-01-01)

Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions
by: Rita T. Lawlor, et al.
Published: (2021-06-01)

POLE/POLD1 mutation and tumor immunotherapy
by: Xiaoting Ma, et al.
Published: (2022-07-01)

EMAST Type of Microsatellite Instability—A Distinct Entity or Blurred Overlap between Stable and MSI Tumors
by: Kristina Vuković Đerfi, et al.
Published: (2023-07-01)

Immunotherapy and Pancreatic Cancer: A Lost Challenge?
by: Carmelo Laface, et al.
Published: (2023-06-01)

Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes
by: Alessandro Di Federico, et al.
Published: (2022-05-01)

The value of cuproptosis-related differential genes in guiding prognosis and immune status in patients with skin cutaneous melanoma
by: Yuming Sun, et al.
Published: (2023-04-01)

The prognostic value of tumor mutational burden related 6-gene-based Risk Score in laryngeal cancer patients
by: Dong Yang, et al.
Published: (2022-11-01)

Case Report: Partial response to single-agent pembrolizumab in a chemotherapy-resistant metastatic pancreatic cancer patient with a high tumor mutation burden
by: Mengyao Dai, et al.
Published: (2023-03-01)

Neoadjuvant Chemotherapy for Colon Cancer
by: Marc T. Roth, et al.
Published: (2020-09-01)

Editorial: Overcoming drug relapse and therapy resistance in NSCLC
by: Sagun Parakh, et al.
Published: (2023-06-01)

Universal cutoff for tumor mutational burden in predicting the efficacy of anti-PD-(L)1 therapy for advanced cancers
by: Shu-Fen Mo, et al.
Published: (2023-05-01)

Assessment of Tumor Mutational Burden in Pediatric Tumors by Real-Life Whole-Exome Sequencing and In Silico Simulation of Targeted Gene Panels: How the Choice of Method Could Affect the Clinical Decision?
by: Hana Noskova, et al.
Published: (2020-01-01)